Lumipulse® G Mesothelin
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative determination Soluble Mesothelin Related Peptides (SMRP) in human serum or plasma.
The assay utilizes proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 294192
Product number 233436
Product number 231203
Click here to navigate
- Contact sales for information
- Details
- Conditions of sale
- Documentation
- Insights
- FAQ
- Related products
- Product inquiry
-
Details
Product benefits
-
Excellent sensitivity: ≤ 0.1 nmol/L.
-
Excellent precision: Typical total CV's: < 6.0%
-
Wide dynamic range: 0.1 - 100 nmol/L
-
30-day calibration interval - no need to run a full calibration for just one sample
-
Less hands on time
-
Eliminates operator to operator issues associated with manual ELISA assays
-
Faster time to result - improved patient care
Clinical background
Malignant mesothelioma is an aggressive tumor with poor prognosis.
Clinical symptoms are not specific and most patients are referred and diagnosed late in the course of the disease.
A reliable histologic diagnosis of malignant mesothelioma can require performing multiple pleural biopsies, however many patients are not clinically able to undergo such invasive procedures.
Therefore, in patients with malignant pleural infusions and a clinical suspicion of malignant mesothelioma, a tumor marker assay is useful for assisting diagnosis, evaluating prognosis and monitoring response to treatment.
Numerous studies 1 - 10 have shown the potential usefulness and utility of the SMRP assay to assist in the diagnosis of malignant mesothelioma.
References
-
Mesothelioma White Paper, DO
-
Pass, H.I. (2001) Malignant Pleural Mesothelioma: Surgical Roles and Novel Therapies. Clinical Lung Cancer 3: 102-117.
-
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-1616
-
Consensus Report (2000) International expert meeting on new advances in the radiology and screening of asbestos-related diseases. Scand J work Environm Health, 26: 449-54
-
Bianchi, C., (2001) Asbestos exposure in Malignant Mesothelioma of the Pleura: A survey of 557 cases. Industrial Health, 39: 161-167
-
Stayner, L., et al. (2013) The Worldwide Pandemic of Asbestos-Related Diseases. Annu. Rev. Public Health. 34:4.1-4.12.
-
Bianchi, C, et al. (2007) Malignant Mesothelioma: Global Incidence and Relationship with Asbestos. Industrial Health, 45: 379-387.
-
Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003; 362(9396):1612-1616
-
Cristaudo, et al. (2011) Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 6(9): 1587-1593.
-
Hollevoet, K. et al. (2012) Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 30:1541-1549.
See the LUMIPULSE G1200 working in this video:
-
-
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileLumipulse G Lung Disease Management brochure.pdf (pdf, 151.32 kb)FileThe South West Area Mesothelioma and Pemetrexed trial.pdf (pdf, 718.72 kb)FileGet access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Jan 6, 2022Oct 15, 2020 -
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry